The specter of generic rivalry has repeatedly loomed around copyright’s famous drug, Viagra, triggering questions about the outlook of similar medicinal ventures. While initial years saw significant returns, the exclusivity end has allowed the way for cheaper copies, likely diminishing profitability and presenting a significant risk for sharehol… Read More